Drug intelligence / Profile preview

BRVLYSIS

Development stage: Preclinical
Lead developer: CZ BioMed
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

BRVLYSIS is a genetically modified oncolytic virus developed by CZ BioMed Corp for the treatment of breast cancer. It is a specific variant of the company's RVLYSIS platform, which utilizes a genetically engineered common-cold-like virus designed to selectively target and destroy malignant cells while sparing normal healthy tissue. BRVLYSIS works through multiple mechanisms: it selectively replicates within breast cancer cells leading to direct lytic rupture, induces apoptosis (programmed cell death), and stimulates a systemic anti-tumor immune response. The drug is currently in the preclinical stage of development, with patents pending in the United States, Europe, and China.

Other names: RVLYSIS variantRVLYSIS platform

Beyond the preview

Go deeper on BRVLYSIS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRVLYSIS.

Explore the full profile